Breo Inverts Traditional Path To COPD Indication For LABA Combinations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline’s NDA for Breo Ellipta sought a COPD indication without prior approval of the combination product or its individual inhaled corticosteroid and long-acting beta agonist components in asthma. A broad development program with extensive dose finding won over a skeptical FDA.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose
The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.